ICG-Fluorescence Imaging for Margin Assessment During Minimally Invasive Colorectal Liver Metastasis Resection.

Alexander L Vahrmeijer, Lissa Wullaert, Hendrik A Marsman, Daan Lips, Wouter J M Derksen, Mark C Boonstra, Babs G Sibinga Mulder, Maxime D Slooter, Okker D Bijlstra, Friso B Achterberg, Babs M Zonderhuis, J Sven D Mieog, Rutger-Jan Swijnenburg, Michael F Gerhards, Hein Putter, Stefan A Bouwense, Jacobus Burggraaf, Jeroen Hagendoorn, Koop Bosscha, Paul D Gobardhan, Mariëlle M E Coolsen

Journal: JAMA network open 2024;7(4):e246548

PMID: 38639939

Abstract

IMPORTANCE

Unintended tumor-positive resection margins occur frequently during minimally invasive surgery for colorectal liver metastases and potentially negatively influence oncologic outcomes.

OBJECTIVE

To assess whether indocyanine green (ICG)-fluorescence-guided surgery is associated with achieving a higher radical resection rate in minimally invasive colorectal liver metastasis surgery and to assess the accuracy of ICG fluorescence for predicting the resection margin status.

DESIGN, SETTING, AND PARTICIPANTS

The MIMIC (Minimally Invasive, Indocyanine-Guided Metastasectomy in Patients With Colorectal Liver Metastases) trial was designed as a prospective single-arm multicenter cohort study in 8 Dutch liver surgery centers. Patients were scheduled to undergo minimally invasive (laparoscopic or robot-assisted) resections of colorectal liver metastases between September 1, 2018, and June 30, 2021.

EXPOSURES

All patients received a single intravenous bolus of 10 mg of ICG 24 hours prior to surgery. During surgery, ICG-fluorescence imaging was used as an adjunct to ultrasonography and regular laparoscopy to guide and assess the resection margin in real time. The ICG-fluorescence imaging was performed during and after liver parenchymal transection to enable real-time assessment of the tumor margin. Absence of ICG fluorescence was favorable both during transection and in the tumor bed directly after resection.

MAIN OUTCOMES AND MEASURES

The primary outcome measure was the radical (R0) resection rate, defined by the percentage of colorectal liver metastases resected with at least a 1 mm distance between the tumor and resection plane. Secondary outcomes were the accuracy of ICG fluorescence in detecting margin-positive (R1; <1 mm margin) resections and the change in surgical management.

RESULTS

In total, 225 patients were enrolled, of whom 201 (116 [57.7%] male; median age, 65 [IQR, 57-72] years) with 316 histologically proven colorectal liver metastases were included in the final analysis. The overall R0 resection rate was 92.4%. Re-resection of ICG-fluorescent tissue in the resection cavity was associated with a 5.0% increase in the R0 percentage (from 87.4% to 92.4%; P < .001). The sensitivity and specificity for real-time resection margin assessment were 60% and 90%, respectively (area under the receiver operating characteristic curve, 0.751; 95% CI, 0.668-0.833), with a positive predictive value of 54% and a negative predictive value of 92%. After training and proctoring of the first procedures, participating centers that were new to the technique had a comparable false-positive rate for predicting R1 resections during the first 10 procedures (odds ratio, 1.36; 95% CI, 0.44-4.24). The ICG-fluorescence imaging was associated with changes in intraoperative surgical management in 56 (27.9%) of the patients.

CONCLUSIONS AND RELEVANCE

In this multicenter prospective cohort study, ICG-fluorescence imaging was associated with an increased rate of tumor margin-negative resection and changes in surgical management in more than one-quarter of the patients. The absence of ICG fluorescence during liver parenchymal transection predicted an R0 resection with 92% accuracy. These results suggest that use of ICG fluorescence may provide real-time feedback of the tumor margin and a higher rate of complete oncologic resection.

Address: Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, the Netherlands.; Department of Surgery, Jeroen Bosch Ziekenhuis, Den Bosch, the Netherlands.; Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.; Department of Surgery, St. Antonius Hospital, Nieuwegein/Regionaal Academisch Kankercentrum Utrecht, Utrecht, the Netherlands.; Department of Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands.; Department of Surgery, Amphia Ziekenhuis, Breda, the Netherlands.; Department of Surgery, University Medical Center Utrecht/Regionaal Academisch Kankercentrum Utrecht, Utrecht, the Netherlands.; Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.; Department of Surgery, Amphia Ziekenhuis, Breda, the Netherlands.; Department of Surgical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.; Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, the Netherlands.; Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.; Centre for Human Drug Research, Leiden, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.; Department of Surgery, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.